Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/13/21
Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13GlobeNewsWire • 05/06/21
Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/12/21
Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/11/21
Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery PlatformGlobeNewsWire • 03/09/21
Capricor Therapeutics - Shockingly Undervalued With Imminent Catalysts In PlaySeeking Alpha • 02/09/21
Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 VaccinesGlobeNewsWire • 02/01/21
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived ExosomesGlobeNewsWire • 01/19/21
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other IndicationsGlobeNewsWire • 01/12/21
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 PatientsGlobeNewsWire • 12/29/20
Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19GlobeNewsWire • 11/24/20
Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/13/20
Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/12/20
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19GlobeNewsWire • 11/09/20
Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12GlobeNewsWire • 11/05/20
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020GlobeNewsWire • 09/23/20
Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/10/20
Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19GlobeNewsWire • 08/25/20
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/09/20
Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/06/20
Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6GlobeNewsWire • 07/30/20
Capricor Therapeutics (CAPR) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/28/20